LETTERS TO THE EDITOR

Non-24-Hour Sleep-Wake Disorder in Sighted Patients: Dealing With an Orphan Disease


Corrado Garbazza, MD
Centre for Chronobiology, Psychiatric Hospital of the University of Basel, Basel, Switzerland; Transfaculty Research Platform Molecular and Cognitive Neurosciences, University of Basel, Basel, Switzerland.

We read with interest the work by Malkani et al., who emphasize the difficulties that can be met in everyday clinical practice by diagnosing and treating non-24-hour sleep-wake disorder (N24SWD), especially in sighted subjects. In fact, while this condition has been early investigated in totally blind people, given its high prevalence and its intuitive pathophysiology (lack of light perception to entrain circadian rhythms), leading some authors to define it “the quintessential circadian rhythm disorder,” less attention has been dedicated to the study of sighted patients.

Apart from the pioneering temporal isolation studies conducted in natural bunkers, where healthy volunteers showed a “free-running rhythm” after deprivation of fundamental time cues, such as daylight, clinical cases of sighted individuals, who spontaneously develop N24SWD have been considered extremely rare. However, reports of similar, sporadic cases are growing in the literature, including some recently published in the Journal of Clinical Sleep Medicine prior to the case series by Malkani et al. Thus, while the epidemiology of sighted N24SWD remains overall unknown, its prevalence may have been underestimated so far, especially since the correct diagnosis is often overlooked.

Secondarily, while specific clock genes have been associated with some circadian rhythm sleep-wake disorders, the molecular mechanisms underlying N24SWD, by lacking familial clusters, are unexplored. Therefore, genome-wide association studies may contribute to better understand the role of genetics, eg, regarding a possible predisposition to disease or response to treatment.

Finally, although the combination of light and melatonin represents the best available therapeutic strategy for sighted N24SWD, circadian rhythm resynchronization is not always achieved. No randomized controlled trials have been conducted so far, and the sole pharmacologic agent on the market (Tasimelteon) is only approved for use in blind patients.

In conclusion, when considering N24SWD in sighted subjects, we are confronted with an “orphan disease,” listed on the European online portal Orphanet (https://www.orpha.net), and which is not only rare and underinvestigated, but also commercially rather unattractive. This condition has nevertheless dramatic consequences for the affected people, due to the severe circadian misalignment, going from the inability to work at regular times, to social isolation, as well as physical and mental disorders.

At our institution, we are collecting clinical cases of N24SWD diagnosed in Switzerland in a database, with the aim to create an international registry of patients assessed worldwide through standardized and comparable methods. This may represent a pivotal step forward to reach further scientific evidence and knowledge about the disorder, moving from the description of individual cases using different tools, to a shared data repository that will help us to better understand the pathophysiology, epidemiology and treatment of sighted N24SWD.

REFERENCES

**SUBMISSION & CORRESPONDENCE INFORMATION**

- Submitted for publication June 11, 2018
- Submitted in final revised form June 11, 2018
- Accepted for publication June 14, 2018

**DISCLOSURE STATEMENT**

This work was performed at the Centre for Chronobiology, University of Basel. The author reports no conflicts of interest.